Product Analyst - Conversational AI

IntegriChain leaders to speak at Informa's fall 2026 MDRP, GTN, and Trade & Channel summits. Sep 22, 2026, 08:00 ET Company experts will deliver sessions on government pricing policy, 340B, gross-to-net strategy, and trade and distribution trends across three premier industry events this fall PHILADELPHIA, Sept. 22, 2026 /PRNewswire/ - IntegriChain, the leading provider of pharma net revenue optimization technology, data, and consulting for the life sciences industry, today announced that its subject matter experts will present at three of Informa Connect's flagship fall conferences: the Medicaid Drug Rebate Program (MDRP) Summit, the Pharma/Biotech Gross-to-Net (GTN) Summit, and Trade & Channel Strategies. Across the three events, IntegriChain leaders will share insights on government pricing and contracting, 340B, gross-to-net forecasting, and the future of pharmaceutical distribution and access. "Government pricing, 340B, gross-to-net, and trade and channel strategy are more interconnected and more consequential than ever for our clients," said Jeff Baab, Partner, Advisory Services with IntegriChain "These conferences give our team the opportunity to bring real-world perspective from the hundreds of manufacturers we support directly to the industry." Baab, Willis Speaks on Evolving Contracting Environment At the Medicaid Drug Rebate Program (MDRP) Summit 2026, taking place October 5-7, 2026, at the Fairmont Chicago Millennium Park in Chicago, IL, Jeff Baab, Partner, Advisory Services at IntegriChain, will present "Updates on Landscape of Government Pricing and Contracting" on Wednesday, October 7, at 9:40 AM. Baab will share his perspective on the evolving government pricing and contracting environment, drawing on his extensive experience advising manufacturers on gross-to-net, contracting, and market access across both commercial and government channels. 340B industry expert Clay Willis, Partner, Advisory Services at IntegriChain will also present "340B Movement to Have All 340B Claims in One System of Record" on Wednesday, October 7 at 10:50 AM, while also offering an update on the recent 340B events such as the the rebate model pilot program #2, contract and in-house pharmacy policies, patient definition, plus other activities occurring in the market. At the Pharma/Biotech Gross-to-Net (GTN) Summit 2026, taking place November 16-18, 2026, at the Hilton at Penn's Landing in Philadelphia, PA, two IntegriChain leaders will take the stage to share perspectives on the issues shaping gross-to-net strategy. On Monday, November 16, at 4:30 PM, Jennifer Sharpe, Vice President, Gross-to-Net Consulting and Facilitator of the Revenue Analytics Collaborative at IntegriChain, will host and moderate "Hot Topic Roundtable Discussions: Sponsored by IntegriChain's Revenue Analytics Collaborative (RAC)" for RAC members. The session will bring together participants from the 800+ member industry peer network Sharpe co-founded to discuss the topics shaping GTN strategy today. On Tuesday, November 17, at 10:55 AM, Walt Worsham, Managing Director at IntegriChain, will present "Drug Pricing Policy & Regulatory Landscape Updates," offering an update on the drug pricing policy and regulatory developments most relevant to gross-to-net forecasting, accruals, and contracting strategy. At Trade & Channel Strategies 2026, taking place December 8-10, 2026, at the W Hotel in Philadelphia, PA, Bill Roth, Senior Vice President and Managing Partner, Consulting and Advisory at IntegriChain, will deliver a keynote address on the state of the channel. His remarks will examine the disruption facing today's pharmacy and distribution landscape, from reimbursement pressure at national retail chains to the downstream effects on specialty and general medicine brands. For more insights on government pricing, 340B, and gross-to-net strategy from IntegriChain's team, visit www.integrichain.com or follow IntegriChain on LinkedIn. About IntegriChain IntegriChain delivers biopharma's only comprehensive data-driven commercialization platform from strategy to operational execution connecting the commercial, financial, and operational dimensions of drug access and profitability. Our ICyte(R) platform integrates technology, data, consulting, and managed services to unify critical workflows replacing manual processes with integrated analytics and precision controls. Biopharma relies on IntegriChain to optimize patient access and net revenue performance, reduce leakage, and strengthen compliance, ensuring every life-changing therapy reaches patients with speed, affordability, and sustainability. Backed by Nordic Capital, a leading sector-specialized private equity investor with a broad portfolio in healthcare and technology. IntegriChain is headquartered in Philadelphia, PA, with a location in Pune, India. For more information, visit www.integrichain.com or follow us on LinkedIn. Media Contact Brandy Jensen, Senior Director Marketing, IntegriChain SOURCE IntegriChain, Inc.

IntegriChain has launched a beta version of its conversational AI assistant with select biopharma partners, aiming to modernise commercial data decision-making. The beta integrates data management, analytics and execution into a single AI-ready environment, focusing on government price reporting, Medicaid rebate adjudication, channel management and specialty commercial excellence. The company has established four Domain Teams to train and validate AI resources across these areas. The AI assistant will respond to natural-language queries and provide root-cause analysis beyond traditional dashboards, with general availability planned for later this year. Built on IntegriChain's ICyte cloud-native platform, the system prioritises explainability and regulatory compliance. To support platform delivery, IntegriChain has appointed John Ristuccia as Senior Vice President of Professional Services and Support.

IntegriChain launches conversational AI beta for biopharma commercial intelligence. Philadelphia, April 27, 2026 - IntegriChain has launched a beta version of its conversational AI assistant with select biopharma partners, advancing its vision to modernize how commercial data is turned into decisions. The beta marks an important step toward a unified decision intelligence layer bringing together data management, analytics, and execution in a single, AI-ready environment. Early use cases focus on high-impact areas including government price reporting, Medicaid rebate adjudication, channel management, and specialty commercial excellence. "This is not about adding AI as a feature; it's about rebuilding the intelligence layer of biopharma commercialization," said Josh Halpern, CEO of IntegriChain. "By embedding explainable, trusted AI into the foundation of the ICyte(R) platform, we're helping customers move faster, operate with confidence, and scale decision-making in an increasingly complex environment." Building trusted AI in biopharma commercial operations. IntegriChain has also established its first four Domain Teams to work with beta customers and lead the training and validation of AI resources in each of the initial subject areas. The Domain Teams draw on IntegriChain's unique depth in the subject areas across consulting, managed services, data, and technology. Together, these teams are training the AI to accurately respond to natural-language queries to explore complex questions and surface insights that go beyond dashboards to root-cause analysis, performance drivers, and cross-domain context delivered directly in workflow. These deployments are shaping a general availability release planned for later this year. IntegriChain's approach prioritizes explainability, auditability, and trust, ensuring AI-generated insights align with regulatory requirements and real-world commercial workflows. The company is embedding AI across the platform rather than treating it as a standalone feature, rebuilding the intelligence layer of biopharma commercial operations from the ground up. ICyte(R) is a cloud-native platform that unifies commercial, financial, and operational data with integrated governance, quality, and compliance controls, creating the foundation for advanced analytics and agentic automation at scale. Leadership investment supporting platform delivery. To support continued platform execution and customer adoption, IntegriChain has strengthened its leadership team with two senior hires focused on global delivery, legal leadership, and technology operations. John Ristuccia has joined IntegriChain as Senior Vice President of Professional Services and Support. With more than 25 years of experience building and scaling global SaaS and data organizations, Ristuccia leads Solutions Delivery, Data Operations, Customer Engagement and Data Implementations, ensuring customers realize full value from ICyte(R) through consistent, high-quality execution. "Great platforms deliver results only when paired with operational excellence," said Ristuccia. "Our focus is translating ICyte's AI-driven capabilities into real-world outcomes for customers at global scale." Kate Barecchia serves as Senior Vice President, Legal at IntegriChain, overseeing the company's global legal strategy, corporate governance, and compliance functions. She brings more than two decades of experience advising high-growth technology companies, with a proven track record of navigating complex regulatory environments and scaling legal operations to support business growth. Prior to joining IntegriChain, Barecchia held the role of Vice President, Deputy General Counsel, and Global Data Privacy Officer at Imperva, where she played a key role in guiding the company through its acquisition. New executive and functional roles have been established to deepen the organization's commitment to advancing AI in pharma and scaling operational capacity. About IntegriChain. IntegriChain delivers biopharma's only comprehensive data-driven commercialization platform from strategy to operational execution, connecting the commercial, financial, and operational dimensions of drug access and profitability. Its ICyte(R) platform integrates technology, data, consulting, and managed services to unify critical workflows replacing manual processes with integrated analytics and precision controls. Biopharma relies on IntegriChain to optimize patient access and net revenue performance, reduce leakage, and strengthen compliance, ensuring every life-changing therapy reaches patients with speed, affordability, and sustainability. Backed by Nordic Capital, a leading sector-specialized private equity investor with a broad portfolio in healthcare and technology. IntegriChain is headquartered in Philadelphia, PA, with a location in Pune, India. For more information, contact IntegriChain Incorporated. or follow IntegriChain Incorporated. on LinkedIn. Media contact. Brandy Jensen, Senior Director of Marketing